Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Non-Current Assets (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Non-Current Assets for 4 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 31.8% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Dec 2025, up 43.92% year-over-year, with the annual reading at $4.5 million for FY2025, 31.8% up from the prior year.
  • Non-Current Assets for Q4 2025 was $4.5 million at LENZ Therapeutics, up from $3.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $46.5 million in Q4 2022, with the low at $648000.0 in Q1 2024.
  • Average Non-Current Assets over 4 years is $18.3 million, with a median of $4.5 million recorded in 2025.
  • The sharpest move saw Non-Current Assets plummeted 98.37% in 2024, then soared 423.61% in 2025.
  • Over 4 years, Non-Current Assets stood at $46.5 million in 2022, then tumbled by 41.03% to $27.4 million in 2023, then plummeted by 87.66% to $3.4 million in 2024, then surged by 31.8% to $4.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $4.5 million, $3.7 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.